AstraZeneca Plc announced its blood cancer drug met the primary endpoint of a final stage trial, the second success for the treatment in a month.
The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.
Calquence, which is already approved by the U.S. drug regulator to treat a rare type of blood cancer, also met the primary endpoint in a trial in May testing the drug in comparison with available treatment.
Via Reuters
